Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.

已完结 10 由大陈发布于 2025/2/1 6:01:43

DOI:10.1056/NEJMoa2406674
作者：Christian T Ruff, Siddharth M Patel, Robert P Giugliano, David A Morrow, Bruce Hug, Julia F Kuder, Erica L Goodrich, Shih-Ann Chen, Shaun G Goodman, Boyoun
文献类型：期刊论文
补充材料：只需要正文

New England Journal of Medicine (NEJM)

Abstract：Background: Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral an

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:知网季铵盐/酰胺类低共熔溶剂的制备及其对纤维素的溶解性能